Ontology highlight
ABSTRACT:
SUBMITTER: Spring LM
PROVIDER: S-EPMC6573012 | biostudies-literature | 2019 Feb
REPOSITORIES: biostudies-literature
Current oncology reports 20190226 3
<h4>Purpose of review</h4>To describe the clinical role of CDK 4/6 inhibitors in hormone receptor-positive (HR+) metastatic breast cancer (HR+ MBC) as well as current controversies and evolving areas of research.<h4>Recent findings</h4>Palbociclib, ribociclib, and abemaciclib are each approved in combination with an aromatase inhibitor or fulvestrant for HR+ MBC. Abemaciclib is also approved as monotherapy for pre-treated patients. Key questions in the field include whether all patients with HR+ ...[more]